Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $39.00

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its target price raised by Canaccord Genuity Group from $37.00 to $39.00 in a report released on Friday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

A number of other brokerages have also recently commented on RARE. Morgan Stanley increased their price objective on shares of Ultragenyx Pharmaceutical from $67.00 to $74.00 and gave the company an “overweight” rating in a research note on Friday, August 21st. TD Cowen cut their target price on shares of Ultragenyx Pharmaceutical from $49.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, September 3rd. Robert W. Baird downgraded shares of Ultragenyx Pharmaceutical from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $40.00 to $16.00 in a report on Thursday, September 3rd. Wells Fargo & Company lowered shares of Ultragenyx Pharmaceutical from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $50.00 to $18.00 in a research report on Thursday, September 3rd. Finally, Barclays dropped their price objective on shares of Ultragenyx Pharmaceutical from $43.00 to $32.00 and set an “overweight” rating for the company in a research note on Friday, September 4th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Ultragenyx Pharmaceutical currently has a consensus rating of “Hold” and a consensus price target of $34.42.

Ultragenyx Pharmaceutical Stock Performance

RARE opened at $14.51 on Friday. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -2.48 and a beta of 0.31. Ultragenyx Pharmaceutical has a one year low of $12.73 and a one year high of $39.89. The business’s fifty day moving average is $23.88 and its two-hundred day moving average is $24.43.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.32. The business had revenue of $214.00 million during the quarter, compared to analysts’ expectations of $183.08 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.The business’s revenue for the quarter was up 28.5% on a year-over-year basis. During the same quarter last year, the business posted ($1.17) earnings per share. On average, analysts predict that Ultragenyx Pharmaceutical will post -3.98 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Versant Capital Management Inc lifted its holdings in Ultragenyx Pharmaceutical by 662.9% in the 2nd quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 1,001 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of Ultragenyx Pharmaceutical during the second quarter worth about $48,000. Harbor Investment Advisory LLC acquired a new position in shares of Ultragenyx Pharmaceutical in the second quarter valued at approximately $52,000. Parallel Advisors LLC raised its position in shares of Ultragenyx Pharmaceutical by 778.4% in the first quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 1,440 shares during the last quarter. Finally, Leonteq Securities AG lifted its stake in shares of Ultragenyx Pharmaceutical by 288.5% during the first quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 1,333 shares during the period. Institutional investors and hedge funds own 97.67% of the company’s stock.

Key Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: The FDA granted full approval to FAYUVI for pediatric patients with Sanfilippo syndrome Type A, also known as MPS IIIA. It is the first approved treatment for the fatal neurodegenerative disease, creating a new commercial opportunity for Ultragenyx where no prior therapy existed. Clinical data showed durable benefit, including a 23.5-point cognitive advantage versus natural history in the pivotal analysis. Ultragenyx Announces Approval of FAYUVI Gene Therapy
• Positive Sentiment: FAYUVI carries a reported $3.95 million list price, potentially making it a significant revenue contributor despite the disease’s small patient population. Ultragenyx expects shipments to qualified treatment centers within 30–60 days and will provide insurance and treatment-access support through its UltraCare program. Ultragenyx Sets $3.95m List Price for Fatal Rare Disease Therapy
• Positive Sentiment: The approval is Ultragenyx’s second gene-therapy approval and sixth FDA approval overall. The company also received a Priority Review Voucher, which could accelerate development or potentially have financial value. US FDA Approves Ultragenyx’s Gene Therapy
• Positive Sentiment: Analysts raised targets after the approval: Cantor Fitzgerald and Canaccord Genuity moved to $39, Citi to $32, and Morgan Stanley to $20. Citi and Canaccord maintained bullish ratings, while Morgan Stanley remained equal weight. Ultragenyx Stock Jumps on Fayuvi Approval and Analyst Target
• Neutral Sentiment: The commercial opportunity is promising but limited by the ultra-rare population. Successful sales will depend on identifying eligible children, establishing treatment centers, securing insurer reimbursement, and managing the complexity of one-time gene-therapy administration.
• Negative Sentiment: FAYUVI’s label includes risks such as liver toxicity, low platelet counts, infusion reactions, thrombotic microangiopathy, and potential malignancy. Long-term safety and real-world adoption remain important uncertainties.
• Negative Sentiment: A Pomerantz law-firm investigation adds an overhang, while the earlier failed Angelman syndrome trial remains a reminder of Ultragenyx’s clinical-development risk. Pomerantz Investor Alert

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company’s work includes therapies for genetic, metabolic and skeletal disorders, with an emphasis on conditions that have limited or no effective treatment options.

Ultragenyx’s marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Dojolvi (triheptanoin), a medical food for long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab), a treatment for homozygous familial hypercholesterolemia.